MOCHA

Commercial feasibility of triggered liposomal drug delivery by means of MOdulated CHAnnels

Coordinatore	RIJKSUNIVERSITEIT GRONINGEN    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	157˙420 €
EC contributo	146˙433 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2011-PoC
Funding Scheme	CSA-SA(POC)
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-06-01   -   2013-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	RIJKSUNIVERSITEIT GRONINGEN  Organization address address: Broerstraat 5 city: GRONINGEN postcode: 9712CP contact info Titolo: Dr. Nome: Dick Cognome: Veldhuis Email: send email Telefono: +31 50 363 4142 Fax: +31 50 363 4500	NL (GRONINGEN)	hostInstitution	146˙433.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The clinical use of most conventional therapies is limited either by insufficient therapeutic drug concentrations at the target tissue or the severe toxic effects of the drug on healthy tissues. The encapsulation of the drug into a liposome as a carrier and its selective delivery to the affected area is one of the solutions. Several liposomal drug formulations have been approved as anticancer therapeutics however, their clinical significance has been limited by slow passive release of the drug at the target site. The idea of ERC-PoC project is to incorporate an engineered ion channel into liposomes as a sensory valve for triggered release of the liposomal content at the target site. The unique advantage of this system is the ability to make liposomes responsive towards a signal with a sensitivity that is not possible to reach with current available systems. This makes the channels excellent candidates for use in drug carriers such as liposomes and exosomes for stimulus-induced drug release. This IP protected technology (two patents) has shown its technological feasibility in the ERC project. Within the ERC-PoC project we want to explore how we are able to enter the market by developing a sound business plan, IPR strategy, market assessment and a product development plan. The outcomes will be consolidated in a sound business plan that will be presented to venture capitalists or other strategic partners.'